CMS 2021 Star Ratings: What are the industry-level takeaways?

RxAnte has taken a closer look at the most recent ratings in our CMS Stars Industry Report, providing insight into the following questions:

1. How did my health plan performance compared to industry peers?

2. How critical is it for plans seeking 4-Star overall ratings to turn their focus to pharmacy-related measures?

3. How did RxAnte clients compare to their peers?

Click the link below for answers to these questions and more.

View Report

Interested in learning how we can help your MAPD plan achieve your quality improvement and Star Rating goals? Contact us today.

Related Resources

6.29.22

by Patricia Powers, PharmD

How Mosaic’s Comprehensive Pharmacy Support Enables Better Care at Home

As the Director of Clinical Services at Mosaic Pharmacy Service, Patricia Powers, Pharm.D. is responsible for overseeing the development and delivery of clinical services for all Mosaic members, RxAnte’s high-touch pharmacy service. This month we asked Dr. Powers to share her insights around at-home care coordination benefiting both the patient and the health system and how Mosaic’s comprehensive pharmacy support can help enable better care at home.

5.25.22

by Tori Erxleben Rush, PharmD

CMS Announcement for Medicare Advantage Part C and D plans

In early April, the Center for Medicaid and Medicare Services shared its Announcement for Medicare Advantage Part C and D plans, incorporating feedback solicited after an Advance Notice was issued in February 2022. Overall, not much has changed since the Advance Notice, however CMS addressed the comments issued by Medicare Advantage stakeholders like MA organizations and prescription drug plan sponsors.

4.4.22

The need for value-based pharmacy services

There is a strong push among physicians to transition to care models that incentivize fewer, more effective treatments. This same perspective should also be held in pharmacy. As we look to a post-pandemic healthcare system, improvements need to be made to remedy these concerns with focuses on barriers to optimal quality and cost--particularly for the medically complex and socially vulnerable.